Filing Details

Accession Number:
0000711377-10-000031
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-10-07 18:20:43
Reporting Period:
2010-10-05
Filing Date:
2010-10-07
Accepted Time:
2010-10-07 18:20:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
711377 Neogen Corp NEOG In Vitro & In Vivo Diagnostic Substances (2835) 382367843
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1189001 H Thomas Reed Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-10-05 398 $9.09 2,086 No 4 M Direct
Common Stock Disposition 2010-10-05 398 $34.06 1,688 No 4 S Direct
Common Stock Acquisiton 2010-10-05 1,628 $8.18 3,316 No 4 M Direct
Common Stock Disposition 2010-10-05 1,628 $34.06 1,688 No 4 S Direct
Common Stock Acquisiton 2010-10-06 91 $8.18 1,779 No 4 M Direct
Common Stock Disposition 2010-10-06 91 $34.05 1,688 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Options (Right-to-buy) Disposition 2010-10-05 398 $0.00 398 $9.09
Common Stock Common Stock Option (Right-to-buy) Disposition 2010-10-05 1,628 $0.00 1,628 $8.18
Common Stock Common Stock Option (Right-to-buy) Disposition 2010-10-06 91 $0.00 91 $8.18
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
15,000 2014-12-21 No 4 M Direct
13,372 2015-10-31 No 4 M Direct
13,281 2015-10-31 No 4 M Direct
Footnotes
  1. The options were granted 12/21/04 as Non-Qualified stock options and became exercisable 33% yearly thereafter.
  2. The options were granted 10/31/05 as Non-Qualified stock options and became exercisable 33% yearly thereafter